{
  "abstract": "Introduction Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are at high risk of cardiovascular (CV)-related hospitalizations (CVH), which are associated with higher mortality. In the phase 3 study ATTR-ACT, treatment with tafamidis significantly reduced CVH versus placebo. Methods This post hoc analysis included patients from ATTR-ACT (30 months) and its long-term extension (LTE; 60 months) receiving tafamidis 80 mg (n = 176) or placebo in ATTR-ACT and switched to tafamidis 80 mg in the LTE (n = 177). CV-related events (CV-related mortality [CVM] and/or recurrent CVH) and CVM were evaluated. Liu–Wei–Yang–Ying and Cox proportional hazard models were used to evaluate time to recurrent CV-related events and CVM, respectively. Results During ATTR-ACT, cumulative incidence of first and recurrent CV-related events in the tafamidis group was lower versus placebo from month 9 and incidence of CVM was lower from month 18. These trends continued throughout the LTE. At month 24, a significant 29% hazard reduction was observed for CV-related events with tafamidis 80 mg versus placebo (incidence 48% vs 61%; hazard ratio [HR] 0.713 [95% CI 0.524–0.970]; p = 0.0310). Hazard reduction remained significant until month 90 with continuous tafamidis 80 mg and was 37% at month 90 (incidence 77% vs 79%; HR 0.629 [95% CI 0.491–0.806; p = 0.0002]). Incidence of CVM with continuous tafamidis 80 mg was lower versus placebo(/tafamidis 80 mg) at month 24 (21% vs 29%) and month 90 (39% vs 47%), with significant hazard reductions of 38% (HR 0.618 [95% CI 0.401–0.954]; p = 0.0299) and 39% (HR 0.607 [95% CI 0.436–0.843]; p = 0.0029), respectively. Similar trends were observed in patients with baseline New York Heart Association (NYHA) functional class I/II but not with baseline NYHA class III. Conclusion Treatment with tafamidis significantly reduced the risk of CV-related events, including recurrent CVH and CVM, as early as month 24. This benefit continued for ≤ 90 months. Graphical abstract available for this article. Trial Registry ClinicalTrial.gov identifiers: NCT01994889; NCT02791230.",
  "abstract_shown": true,
  "affiliations": [
    "Referral Center for Cardiac Amyloidosis, CHU Henri Mondor",
    "Stanford University School of Medicine",
    "Tuscan Regional Amyloidosis Referral Centre,, Careggi University Hospital",
    "Pfizer Inc",
    "Department of Cardiovascular Diseases, Mayo Clinic"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Thibaud Damy"
    },
    {
      "affs": [
        1
      ],
      "name": "Ronald Witteles"
    },
    {
      "affs": [
        2
      ],
      "name": "Francesco Cappelli"
    },
    {
      "affs": [
        3
      ],
      "name": "Ronnie Wang"
    },
    {
      "affs": [
        4
      ],
      "name": "Martha Grogan"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/85f05k5cvnqj7.bib",
  "cited_by": 0,
  "doi": "10.1007/s40119-026-00470-8",
  "fulltext_url": "https://doi.org/10.1007/s40119-026-00470-8",
  "id": "85f05k5cvnqj7",
  "issns": [
    "2193-8261",
    "2193-6544"
  ],
  "landing_url": "https://doi.org/10.1007/s40119-026-00470-8",
  "language": "en",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC666-701"
    ],
    [
      "openalex",
      "1312|Amyloidosis: Diagnosis, Treatment, Outcomes"
    ]
  ],
  "openalex": "W7204450077",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s40119-026-00470-8.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-08-01",
  "publisher": "Adis, Springer Healthcare",
  "ris": "https://research.draconitic.com/paper/85f05k5cvnqj7.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:46:35Z",
      "native_id": "9e3a75587ae447619062cd15f7661287",
      "source": "doaj",
      "url": "https://doi.org/10.1007/s40119-026-00470-8"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Amyloidosis: Diagnosis, Treatment, Outcomes",
      "subfield": "molecular-biology"
    }
  ],
  "title": "Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension",
  "title_text": "Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:35Z",
  "url": "https://research.draconitic.com/paper/85f05k5cvnqj7",
  "venue": "Cardiology and Therapy",
  "versions": []
}